Compounds > ibuprofen arginine
Page last updated: 2024-12-11

ibuprofen arginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ibuprofen arginine: trade name Spedifen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9864669
CHEMBL ID4594450
SCHEMBL ID43030
MeSH IDM0277856

Synonyms (18)

Synonym
ibuprofen arginine salt
D08058
zafen (tn)
ibuprofen arginine
AKOS016012259
57469-82-6
ibuprofen l-arginine
SCHEMBL43030
(s)-2-amino-5-guanidinopentanoic acid compound with 2-(4-isobutylphenyl)propanoic acid (1:1)
DTXSID30432072
mfcd23701748
AS-10612
(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-[4-(2-methylpropyl)phenyl]propanoic acid
AMY520
l-arginine, |a-methyl-4-(2-methylpropyl)benzeneacetate
Q27294011
CHEMBL4594450
(s)-2-amino-5-guanidinopentanoicacidcompoundwith2-(4-isobutylphenyl)propanoicacid(1:1)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Substantial inter-subject variability in the evaluated pharmacokinetic parameters was observed in the present study."( Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
Bani, M; Brogin, G; Della Pepa, C; Eandi, M; Fornasini, G; Gallina, M; Monti, N; Persiani, S; Strolin Benedetti, M; Zara, G, 1997)		0.51
" The primary objective of this study was to compare the 12-h pharmacokinetic profile of S(+)-ibuprofen following administration of single doses of ibuprofen arginate (600 mg) and dexibuprofen (400 mg) in healthy volunteers."( A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers.
Azanza, JR; Campanero, MA; Esteras, A; García-Quetglas, E; Gil-Aldea, I; Muñoz-Juarez, MJ; Sádaba, B, 2006)		0.33
" Compared with dexibuprofen, ibuprofen arginate demonstrated a 45% higher maximum concentration (C(max)), and a time to peak concentration (T(max)) 2 h sooner."( A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers.
Azanza, JR; Campanero, MA; Esteras, A; García-Quetglas, E; Gil-Aldea, I; Muñoz-Juarez, MJ; Sádaba, B, 2006)		0.33
"Currently, several ibuprofen compounds are available on the market, mainly differing in terms of pharmaceutical composition that influence the pharmacokinetic profile and eventually the onset of drug action."( Clinical pharmacokinetics of ibuprofen arginine.
Cattaneo, D; Clementi, E, 2010)		0.65
" The pharmacokinetic stereoselectivity was higher after oral administration than that after intravenous administration."( Pharmacokinetics of ibuprofen enantiomers in rats after intravenous and oral administration of ibuprofen arginate.
Han, J; Liu, HC; Wang, XL; Zhang, D, 2012)		0.38

Bioavailability

ExcerptReferenceRelevance
" Tmax values of S(+)- and (-)R-ibuprofen after a single dose of 400 mg of each enantiomer did not differ significantly from the corresponding parameters obtained after a single dose of 800 mg of racemic ibuprofen arginine, indicating that the absorption rate of (-)R- and (+)S-ibuprofen is not different when the two enantiomers are administered alone or as a racemic compound."( Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
Bani, M; Brogin, G; Della Pepa, C; Eandi, M; Fornasini, G; Gallina, M; Monti, N; Persiani, S; Strolin Benedetti, M; Zara, G, 1997)		0.7
" Ibuprofen arginate and dexibuprofen showed similar bioavailability for S(+)-ibuprofen."( A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers.
Azanza, JR; Campanero, MA; Esteras, A; García-Quetglas, E; Gil-Aldea, I; Muñoz-Juarez, MJ; Sádaba, B, 2006)		0.33
" Currently available in the market are preparations in which bioavailability of ibuprofen is increased by salification with various salts."( Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects.
Cattaneo, D; Clementi, E; Cuzzocrea, S; De Palma, C; Di Paola, R; Mazzon, E; Perrotta, C; Trabucchi, E, 2009)		0.35

Dosage Studied

ExcerptRelevanceReference
"Co-amorphous mixtures have rarely been formulated as oral dosage forms, even though they have been shown to stabilize amorphous drugs in the solid state and enhance the dissolution properties of poorly soluble drugs."( Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
Korhonen, O; Laitinen, R; Ojarinta, R; Saarinen, J; Strachan, CJ, 2018)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (9.09)18.2507
2000's12 (54.55)29.6817
2010's8 (36.36)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.27 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index74.85 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (50.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (50.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (45.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open-label, Single-center, Single-dose, Two Treatment, Two-sequence, Two-period, Two-cohort, Two-way Crossover Bioequivalence Study of Two Ibuprofen Arginine Granules 400 mg Formulations Under Fasting and Fed Conditions in Chinese Healthy Ad [NCT05737069]Phase 184 participants (Actual)Interventional2023-04-19Completed
Pain Reduction and Changes in Upper Limb Function Produced by Physiotherapy, Ibuprofen Arginine, Gabapentin and the Absence of Treatment, in Carpal Tunnel Syndrome [NCT04025203]Phase 480 participants (Anticipated)Interventional2019-08-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
n(g),n(g')-dimethyl-l-arginine
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine		2.1310alpha-amino acid
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		3.3911acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		10.022211monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.5720aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.1710benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.4720aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
mannitol
[no description available]		2.1710mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		10.022211arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
xylitol
xylooligosaccharide: structure in first source. pentitol : An alditol obtained by reduction of any pentose.. xylooligosaccharide : An oligosaccharide comprised of xylose residues.		2.1710
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		2.1710pyrrolidin-2-ones
n,n-dimethylarginine
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine. N(omega),N(omega)-dimethyl-L-arginine : A L-arginine derivative having two methyl groups both attached to the primary amino moiety of the guanidino group.		2.1310dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor
solufenum
solufenum: water-soluble salt of ibuprofen; structure in fourth source		2.0210
ketoprofen lysine
ketoprofen lysine: lysine salt of ketoprofen; structure in first source		2.1710
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0510aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.1510
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1510
Polyarthritis
[description not available]		02.0510
Arthritis
Acute or chronic inflammation of JOINTS.		02.0510
Acute Post-operative Pain
[description not available]		06.4144
Pain, Postoperative
Pain during the period after surgery.		06.4144
Lesion of Sciatic Nerve
[description not available]		02.0710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0710
Innate Inflammatory Response
[description not available]		02.0710
Nerve Pain
[description not available]		02.0710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0710
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.0710
Extravascular Hemolysis
[description not available]		02.0210
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.0210
Gastroduodenal Ulcer
[description not available]		03.4111
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		03.4111
Chronic Illness
[description not available]		04.3822
Pericementitis
[description not available]		03.4111
Odontalgia
[description not available]		03.4111
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		04.3822
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		03.4111
Toothache
Pain in the adjacent areas of the teeth.		03.4111
Nasal Bleeding
[description not available]		03.4111
Bilateral Headache
[description not available]		03.4111
Epistaxis
Bleeding from the nose.		03.4111
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		03.4111
Low Back Ache
[description not available]		03.4111
Low Back Pain
Acute or chronic pain in the lumbar or sacral regions, which may be associated with musculo-ligamentous SPRAINS AND STRAINS; INTERVERTEBRAL DISK DISPLACEMENT; and other conditions.		03.4111
Abdominal Migraine
[description not available]		03.3811
Acute Disease
Disease having a short and relatively severe course.		03.3811
Migraine Disorders
A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)		03.3811
Pyrexia
[description not available]		03.3911
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		03.3911